Dekel Gelbman and How Machine Learning is Changing Rare Disease Diagnosis

October 11, 2018

MoneyBall Medicine Podcast 

“FDNA is an innovative digital health company that develops technologies and SASS platforms used by thousands of clinicians researchers and lab sites locally in the clinical genomic space. The main mission of the company is to give hope to children with rare diseases and their families. FDNA which was founded in 2011, uses a combination of computer vision, deep learning, and artificial intelligence to analyze patient symptoms, physical features, and genomic data in combination with a network of thousands of genetics professionals worldwide. Then they drive scientific insights to improve and accelerate diagnostics and therapeutics impacting the lives of children with rare diseases.”

 

The article features insights on how FDNA’s integration of machine learning is revolutionizing healthcare, particularly in diagnosing rare diseases. It discusses the Face2Gene platform, which employs advanced machine-learning algorithms to analyze facial features and identify genetic disorders with high accuracy. By leveraging a vast database and sophisticated pattern recognition, FDNA’s technology provides quicker and more accurate diagnoses compared to traditional methods.